Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression

The mechanisms of action of the rapid antidepressant effects of ketamine, an N -methyl- D -aspartate glutamate receptor antagonist, have not been fully elucidated. This study examined the effects of ketamine on ligand binding to a metabotropic glutamatergic receptor (mGluR5) in individuals with majo...

Full description

Saved in:
Bibliographic Details
Published inMolecular psychiatry Vol. 23; no. 4; pp. 824 - 832
Main Authors Esterlis, I, DellaGioia, N, Pietrzak, R H, Matuskey, D, Nabulsi, N, Abdallah, C G, Yang, J, Pittenger, C, Sanacora, G, Krystal, J H, Parsey, R V, Carson, R E, DeLorenzo, C
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.04.2018
Nature Publishing Group
Subjects
631/337
631/378
Adult
Antidepressants
Antidepressive Agents - pharmacology
Anxiety disorders
Behavioral Sciences
Biological Psychology
Biomedical engineering
Brain - metabolism
Carbon Radioisotopes
Case-Control Studies
Comparative analysis
Depression - diagnostic imaging
Depressive Disorder, Major - diagnostic imaging
Depressive Disorder, Major - metabolism
Dosage and administration
Drug abuse
Excitatory Amino Acid Antagonists - pharmacology
Female
Glutamatergic transmission
Glutamic Acid - metabolism
Glutamic acid receptors (metabotropic)
Health care
Humans
Internalization
Intravenous administration
Ketamine
Ketamine - metabolism
Ketamine - pharmacology
Ligands
Major depressive disorder
Male
Medicine
Medicine & Public Health
Mental depression
Mental disorders
Metabotropic glutamate receptors
Metabotropic receptors
N-Methyl-D-aspartic acid receptors
Neurosciences
original-article
Pharmacotherapy
Positron emission tomography
Positron-Emission Tomography - methods
Proteins
Psychiatry
Radiation
Receptor, Metabotropic Glutamate 5 - drug effects
Receptor, Metabotropic Glutamate 5 - metabolism
Spectrum analysis
Substance abuse treatment
Tomography
Online AccessGet full text

Cover

Abstract The mechanisms of action of the rapid antidepressant effects of ketamine, an N -methyl- D -aspartate glutamate receptor antagonist, have not been fully elucidated. This study examined the effects of ketamine on ligand binding to a metabotropic glutamatergic receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls. Thirteen healthy and 13 MDD nonsmokers participated in two [ 11 C]ABP688 positron emission tomography (PET) scans on the same day—before and during intravenous ketamine administration—and a third scan 1 day later. At baseline, significantly lower [ 11 C]ABP688 binding was detected in the MDD as compared with the control group. We observed a significant ketamine-induced reduction in mGluR5 availability (that is, [ 11 C]ABP688 binding) in both MDD and control subjects (average of 14±9% and 19±22%, respectively; P <0.01 for both), which persisted 24 h later. There were no differences in ketamine-induced changes between MDD and control groups at either time point ( P =0.8). A significant reduction in depressive symptoms was observed following ketamine administration in the MDD group ( P <0.001), which was associated with the change in binding ( P <0.04) immediately after ketamine. We hypothesize that glutamate released after ketamine administration moderates mGluR5 availability; this change appears to be related to antidepressant efficacy. The sustained decrease in binding may reflect prolonged mGluR5 internalization in response to the glutamate surge.
AbstractList The mechanisms of action of the rapid antidepressant effects of ketamine, an N-methyl-D-aspartate glutamate receptor antagonist, have not been fully elucidated. This study examined the effects of ketamine on ligand binding to a metabotropic glutamatergic receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls. Thirteen healthy and 13 MDD nonsmokers participated in two [ C]ABP688 positron emission tomography (PET) scans on the same day-before and during intravenous ketamine administration-and a third scan 1 day later. At baseline, significantly lower [ C]ABP688 binding was detected in the MDD as compared with the control group. We observed a significant ketamine-induced reduction in mGluR5 availability (that is, [ C]ABP688 binding) in both MDD and control subjects (average of 14±9% and 19±22%, respectively; P<0.01 for both), which persisted 24 h later. There were no differences in ketamine-induced changes between MDD and control groups at either time point (P=0.8). A significant reduction in depressive symptoms was observed following ketamine administration in the MDD group (P<0.001), which was associated with the change in binding (P<0.04) immediately after ketamine. We hypothesize that glutamate released after ketamine administration moderates mGluR5 availability; this change appears to be related to antidepressant efficacy. The sustained decrease in binding may reflect prolonged mGluR5 internalization in response to the glutamate surge.
The mechanisms of action of the rapid antidepressant effects of ketamine, an NMDA glutamate receptor antagonist, have not been fully elucidated. This study examined effects of ketamine on ligand binding to a metabotropic glutamatergic receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls. Thirteen healthy and thirteen MDD nonsmokers participated in two [ 11 C]ABP688 positron emission tomography (PET) scans on the same day – before and during intravenous ketamine administration – and a third scan 1 day later. At baseline, significantly lower [ 11 C]ABP688 binding was detected in the MDD as compared to the control group. We observed a significant ketamine-induced reduction in mGluR5 availability, (i.e. [ 11 C]ABP688 binding), in both MDD and control subjects (average of 14±9% and 19±22%, respectively; p<0.01 for both), which persisted 24 hours later. There were no differences in ketamine-induced changes between MDD and control groups at either time point (p=0.8). A significant reduction in depressive symptoms was observed following ketamine administration in the MDD group (p<0.001), which was associated with the change in binding (p<0.04) immediately post ketamine. We hypothesize that glutamate released after ketamine administration moderates mGluR5 availability; this change appears to be related to antidepressant efficacy. The sustained decrease in binding may reflect prolonged mGluR5 internalization in response to the glutamate surge.
The mechanisms of action of the rapid antidepressant effects of ketamine, an N-methyl-D-aspartate glutamate receptor antagonist, have not been fully elucidated. This study examined the effects of ketamine on ligand binding to a metabotropic glutamatergic receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls. Thirteen healthy and 13 MDD nonsmokers participated in two [[sup.11]C]ABP688 positron emission tomography (PET) scans on the same day--before and during intravenous ketamine administration--and a third scan 1 day later. At baseline, significantly lower [[sup.11]C]ABP688 binding was detected in the MDD as compared with the control group. We observed a significant ketamine-induced reduction in mGluR5 availability (that is, [[sup.11]C]ABP688 binding) in both MDD and control subjects (average of 14[+ or -]9% and 19[+ or -]22%, respectively; P [less than] 0.01 for both), which persisted 24 h later. There were no differences in ketamine-induced changes between MDD and control groups at either time point (P=0.8). A significant reduction in depressive symptoms was observed following ketamine administration in the MDD group (P [less than] 0.001), which was associated with the change in binding (P [less than] 0.04) immediately after ketamine. We hypothesize that glutamate released after ketamine administration moderates mGluR5 availability; this change appears to be related to antidepressant efficacy. The sustained decrease in binding may reflect prolonged mGluR5 internalization in response to the glutamate surge.
The mechanisms of action of the rapid antidepressant effects of ketamine, an N-methyl-D-aspartate glutamate receptor antagonist, have not been fully elucidated. This study examined the effects of ketamine on ligand binding to a metabotropic glutamatergic receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls. Thirteen healthy and 13 MDD nonsmokers participated in two [11 C]ABP688 positron emission tomography (PET) scans on the same day--before and during intravenous ketamine administration--and a third scan 1 day later. At baseline, significantly lower [11 C]ABP688 binding was detected in the MDD as compared with the control group. We observed a significant ketamine-induced reduction in mGluR5 availability (that is, [11 C]ABP688 binding) in both MDD and control subjects (average of 14±9% and 19±22%, respectively; P<0.01 for both), which persisted 24 h later. There were no differences in ketamine-induced changes between MDD and control groups at either time point (P=0.8). A significant reduction in depressive symptoms was observed following ketamine administration in the MDD group (P<0.001), which was associated with the change in binding (P<0.04) immediately after ketamine. We hypothesize that glutamate released after ketamine administration moderates mGluR5 availability; this change appears to be related to antidepressant efficacy. The sustained decrease in binding may reflect prolonged mGluR5 internalization in response to the glutamate surge.
The mechanisms of action of the rapid antidepressant effects of ketamine, an N -methyl- D -aspartate glutamate receptor antagonist, have not been fully elucidated. This study examined the effects of ketamine on ligand binding to a metabotropic glutamatergic receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls. Thirteen healthy and 13 MDD nonsmokers participated in two [ 11 C]ABP688 positron emission tomography (PET) scans on the same day—before and during intravenous ketamine administration—and a third scan 1 day later. At baseline, significantly lower [ 11 C]ABP688 binding was detected in the MDD as compared with the control group. We observed a significant ketamine-induced reduction in mGluR5 availability (that is, [ 11 C]ABP688 binding) in both MDD and control subjects (average of 14±9% and 19±22%, respectively; P <0.01 for both), which persisted 24 h later. There were no differences in ketamine-induced changes between MDD and control groups at either time point ( P =0.8). A significant reduction in depressive symptoms was observed following ketamine administration in the MDD group ( P <0.001), which was associated with the change in binding ( P <0.04) immediately after ketamine. We hypothesize that glutamate released after ketamine administration moderates mGluR5 availability; this change appears to be related to antidepressant efficacy. The sustained decrease in binding may reflect prolonged mGluR5 internalization in response to the glutamate surge.
The mechanisms of action of the rapid antidepressant effects of ketamine, an N-methyl-D-aspartate glutamate receptor antagonist, have not been fully elucidated. This study examined the effects of ketamine on ligand binding to a metabotropic glutamatergic receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls. Thirteen healthy and 13 MDD nonsmokers participated in two [[sup.11]C]ABP688 positron emission tomography (PET) scans on the same day--before and during intravenous ketamine administration--and a third scan 1 day later. At baseline, significantly lower [[sup.11]C]ABP688 binding was detected in the MDD as compared with the control group. We observed a significant ketamine-induced reduction in mGluR5 availability (that is, [[sup.11]C]ABP688 binding) in both MDD and control subjects (average of 14[+ or -]9% and 19[+ or -]22%, respectively; P [less than] 0.01 for both), which persisted 24 h later. There were no differences in ketamine-induced changes between MDD and control groups at either time point (P=0.8). A significant reduction in depressive symptoms was observed following ketamine administration in the MDD group (P [less than] 0.001), which was associated with the change in binding (P [less than] 0.04) immediately after ketamine. We hypothesize that glutamate released after ketamine administration moderates mGluR5 availability; this change appears to be related to antidepressant efficacy. The sustained decrease in binding may reflect prolonged mGluR5 internalization in response to the glutamate surge. Molecular Psychiatry (2018) 23, 824-832; doi: 10.1038/mp.2017.58; published online 11 April 2017
Audience Academic
Author Krystal, J H
Pietrzak, R H
Abdallah, C G
Sanacora, G
Nabulsi, N
Carson, R E
Pittenger, C
Parsey, R V
Esterlis, I
Yang, J
DellaGioia, N
Matuskey, D
DeLorenzo, C
AuthorAffiliation 5 U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System
6 Stony Brook University Department of Preventive Medicine
7 Stony Brook University Department of Psychiatry
9 Stony Brook University Department of Radiology
2 Yale University Department of Radiology and Biomedical Imaging
1 Yale University Department of Psychiatry
8 Stony Brook University Department of Biomedical Engineering
4 Yale University Department of Neuroscience
3 Yale University Department of Biomedical Engineering
AuthorAffiliation_xml – name: 4 Yale University Department of Neuroscience
– name: 6 Stony Brook University Department of Preventive Medicine
– name: 2 Yale University Department of Radiology and Biomedical Imaging
– name: 7 Stony Brook University Department of Psychiatry
– name: 1 Yale University Department of Psychiatry
– name: 5 U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System
– name: 8 Stony Brook University Department of Biomedical Engineering
– name: 3 Yale University Department of Biomedical Engineering
– name: 9 Stony Brook University Department of Radiology
Author_xml – sequence: 1
  givenname: I
  surname: Esterlis
  fullname: Esterlis, I
  email: irina.esterlis@yale.edu
  organization: Department of Psychiatry, Yale University, U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System
– sequence: 2
  givenname: N
  surname: DellaGioia
  fullname: DellaGioia, N
  organization: Department of Psychiatry, Yale University
– sequence: 3
  givenname: R H
  surname: Pietrzak
  fullname: Pietrzak, R H
  organization: Department of Psychiatry, Yale University, U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System
– sequence: 4
  givenname: D
  surname: Matuskey
  fullname: Matuskey, D
  organization: Department of Psychiatry, Yale University, Department of Radiology and Biomedical Imaging, Yale University
– sequence: 5
  givenname: N
  surname: Nabulsi
  fullname: Nabulsi, N
  organization: Department of Radiology and Biomedical Imaging, Yale University
– sequence: 6
  givenname: C G
  surname: Abdallah
  fullname: Abdallah, C G
  organization: Department of Psychiatry, Yale University, U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System
– sequence: 7
  givenname: J
  surname: Yang
  fullname: Yang, J
  organization: Department of Preventive Medicine, Stony Brook University
– sequence: 8
  givenname: C
  orcidid: 0000-0003-2117-9321
  surname: Pittenger
  fullname: Pittenger, C
  organization: Department of Psychiatry, Yale University
– sequence: 9
  givenname: G
  surname: Sanacora
  fullname: Sanacora, G
  organization: Department of Psychiatry, Yale University
– sequence: 10
  givenname: J H
  surname: Krystal
  fullname: Krystal, J H
  organization: Department of Psychiatry, Yale University, U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System, Department of Neuroscience, Yale University
– sequence: 11
  givenname: R V
  surname: Parsey
  fullname: Parsey, R V
  organization: Department of Psychiatry, Stony Brook University, Department of Biomedical Engineering, Stony Brook University, Department of Radiology, Stony Brook University
– sequence: 12
  givenname: R E
  surname: Carson
  fullname: Carson, R E
  organization: Department of Radiology and Biomedical Imaging, Yale University, Department of Biomedical Engineering, Yale University
– sequence: 13
  givenname: C
  surname: DeLorenzo
  fullname: DeLorenzo, C
  organization: Department of Psychiatry, Stony Brook University, Department of Biomedical Engineering, Stony Brook University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28397841$$D View this record in MEDLINE/PubMed
BookMark eNptkt9qFDEUxoNUbLt64wPIgHfKrMkkmcl4UVhLrWLBIvVKJGTyZ3vKTGacZCr7HL6wGXdtrSwJ5CTnd7584eQYHfjeW4SeE7wkmIo33bAsMKmWXDxCR4RVZc55JQ5STHmdMyLYIToO4QbjOcmfoMNC0LoSjByhX59sVB14m4M3k7YmG21aI_Q-A5915-30hWfqVkGrGmghbjIImQqh16Biwn9CvM6UTzOCscNoQ0hhUglD74N9O-e-EXL6ffXushQibU12eXaVQafW4NdZiJPZzFftitPFT9Fjp9pgn-3WBfr6_uzq9EN-8fn84-nqIteM4Zg3ljpBmasZbZoK26puSIG14Q4XwjrFK1q6yhnKS42J5rRwxpSUcUKNY7ihC3Sy1R2mprNGWx9H1cphTN7GjewVyIcZD9dy3d9KXtKyZHUSeLkTGPsfkw1R3vTT6JNnmRpSckJqVtxTa9VaCd71SUx3ELRccUoE_WNpgZZ7qDSM7UCnhjtI5w8KXvzr_s72394m4NUW0GMfwmjdHUKwnD-O7IbZZyW5SDD-D9YQ1fwNkg1o95e83paEpOvXdrx__R76N_Ez1E8
CitedBy_id crossref_primary_10_1007_s00259_018_4237_3
crossref_primary_10_1111_ejn_15358
crossref_primary_10_1007_s00259_018_4252_4
crossref_primary_10_1016_j_phrs_2024_107081
crossref_primary_10_3390_ph16081127
crossref_primary_10_1038_s41398_023_02346_0
crossref_primary_10_1016_j_neuropharm_2024_110018
crossref_primary_10_1038_s41386_022_01368_4
crossref_primary_10_1001_jamanetworkopen_2020_13211
crossref_primary_10_1002_hbm_24976
crossref_primary_10_1111_jnc_15657
crossref_primary_10_1162_imag_a_00126
crossref_primary_10_1093_ijnp_pyab084
crossref_primary_10_1016_j_neuroimage_2018_10_017
crossref_primary_10_1016_j_bbih_2020_100108
crossref_primary_10_1016_j_biopsych_2017_08_025
crossref_primary_10_1111_cns_12998
crossref_primary_10_1016_S2215_0366_23_00183_9
crossref_primary_10_1038_s41380_018_0252_9
crossref_primary_10_1007_s11307_018_1257_0
crossref_primary_10_1016_j_pnpbp_2020_110041
crossref_primary_10_1016_j_pbb_2022_173446
crossref_primary_10_3390_molecules25204749
crossref_primary_10_3390_brainsci9080183
crossref_primary_10_1038_s41398_021_01763_3
crossref_primary_10_1177_2470547019837712
crossref_primary_10_1016_j_jad_2020_12_176
crossref_primary_10_1038_s41380_022_01465_2
crossref_primary_10_1016_j_pharmthera_2021_107875
crossref_primary_10_1080_00332747_2022_2068931
crossref_primary_10_3390_ijms21062148
crossref_primary_10_1177_24705470221105804
crossref_primary_10_1016_j_ynstr_2019_100169
crossref_primary_10_3389_fnins_2023_1213941
crossref_primary_10_1146_annurev_neuro_110920_040422
crossref_primary_10_3390_ijms232315114
crossref_primary_10_1016_j_euroneuro_2018_12_001
crossref_primary_10_1038_s41598_017_09991_8
crossref_primary_10_3389_fnmol_2018_00376
crossref_primary_10_1007_s00406_018_0942_y
crossref_primary_10_1038_s41586_023_06204_3
crossref_primary_10_1016_j_biopsych_2020_12_006
crossref_primary_10_1080_15622975_2021_1878427
crossref_primary_10_1371_journal_pone_0245580
crossref_primary_10_1038_s41380_023_01960_0
crossref_primary_10_1007_s00213_024_06571_3
crossref_primary_10_1016_j_bpsc_2022_11_005
crossref_primary_10_3390_ph11030083
crossref_primary_10_1016_j_neuron_2019_10_003
crossref_primary_10_1016_j_jad_2023_07_003
crossref_primary_10_1016_j_jad_2020_03_104
crossref_primary_10_1038_s41386_024_01913_3
crossref_primary_10_1038_s41386_023_01629_w
crossref_primary_10_1016_j_nsa_2024_104079
crossref_primary_10_1038_s41598_020_63389_7
crossref_primary_10_1177_24705470231215001
crossref_primary_10_1016_j_pharmthera_2018_05_010
crossref_primary_10_1016_j_pnpbp_2023_110910
crossref_primary_10_1016_j_phrs_2021_105542
crossref_primary_10_1038_s41380_021_01246_3
crossref_primary_10_1016_j_bbr_2019_112347
crossref_primary_10_1111_jnc_15615
crossref_primary_10_1177_24705470231154842
crossref_primary_10_3389_fpsyt_2018_00767
crossref_primary_10_1177_2470547018796102
crossref_primary_10_1016_j_biopsych_2018_03_001
crossref_primary_10_1093_ijnp_pyae044
crossref_primary_10_3390_biom14020163
crossref_primary_10_1007_s10571_018_0645_y
crossref_primary_10_3389_fmed_2019_00268
crossref_primary_10_1177_1536012118788636
crossref_primary_10_1002_jlcr_3802
crossref_primary_10_1038_s41386_018_0136_3
crossref_primary_10_1007_s00213_023_06325_7
crossref_primary_10_1038_s41380_024_02541_5
crossref_primary_10_1002_syn_22041
crossref_primary_10_1007_s00213_017_4823_2
crossref_primary_10_1097_WNP_0000000000000729
crossref_primary_10_1016_j_euroneuro_2020_08_007
crossref_primary_10_1016_j_neubiorev_2019_08_019
crossref_primary_10_1016_j_neuron_2019_07_011
crossref_primary_10_1016_j_bpsc_2021_11_010
crossref_primary_10_1038_s41398_021_01327_5
crossref_primary_10_1016_j_bpsc_2024_11_014
crossref_primary_10_1177_0271678X19886316
crossref_primary_10_1093_brain_awz118
crossref_primary_10_1016_j_biopsych_2021_04_004
crossref_primary_10_1038_s41386_022_01441_y
crossref_primary_10_1016_j_biopsych_2022_10_018
crossref_primary_10_3389_fpsyt_2021_637863
crossref_primary_10_1038_s41398_020_01152_2
crossref_primary_10_3390_ijms25126357
crossref_primary_10_1038_s41386_025_02085_4
crossref_primary_10_1073_pnas_2305772120
crossref_primary_10_1016_j_cmpb_2024_108319
crossref_primary_10_1016_j_euroneuro_2022_09_006
crossref_primary_10_1176_appi_ajp_2018_18020138
crossref_primary_10_1073_pnas_1818871116
crossref_primary_10_1016_j_biopsych_2024_09_008
crossref_primary_10_1038_s41398_018_0311_7
crossref_primary_10_1038_s44220_025_00386_7
Cites_doi 10.1038/sj.jcbfm.9600607
10.1016/S0924-977X(96)00039-9
10.1016/j.biopsych.2014.06.024
10.1073/pnas.96.15.8739
10.1523/JNEUROSCI.0995-04.2004
10.1038/sj.jcbfm.9600493
10.1016/j.neubiorev.2011.05.014
10.1016/j.brainresbull.2011.01.005
10.2967/jnumed.107.039578
10.1016/j.biopsych.2007.03.017
10.1038/jcbfm.2011.55
10.1016/S1734-1140(13)71511-1
10.1016/S0028-3908(98)00129-4
10.1007/s00213-009-1758-2
10.2165/11533230-000000000-00000
10.1523/JNEUROSCI.21-06-01838.2001
10.1126/science.1190287
10.2967/jnumed.106.038075
10.1038/jcbfm.2011.105
10.1111/j.1460-9568.2006.04798.x
10.1016/j.biopsych.2010.12.023
10.1523/JNEUROSCI.4208-14.2015
10.1016/j.biopsych.2013.03.026
10.1001/archpsyc.1961.01710120031004
10.1002/syn.21656
10.1023/A:1024465317902
10.1038/nature09613
10.1016/S0028-3908(02)00062-X
10.1038/mp.2016.34
10.1016/j.brainresbull.2012.01.010
10.1038/nature17998
10.1038/jcbfm.2009.195
10.1016/j.bbr.2012.08.016
10.1093/cercor/12.6.625
10.1001/jamapsychiatry.2016.0838
10.1073/pnas.1208494109
10.1038/sj.bjp.0703923
10.1111/j.1749-6632.1999.tb11316.x
10.1176/ajp.154.6.805
10.1038/nrd2462
10.1016/j.nucmedbio.2007.07.009
10.1016/S0140-6736(15)60692-4
10.4088/JCP.v69n0719
10.1016/j.neuroimage.2013.05.006
10.1097/JCP.0b013e31820ebd2c
10.1038/nm.4050
10.1002/gps.776
10.1016/S0006-3223(99)00230-9
10.1001/archpsyc.64.2.193
10.1002/1097-4679(198409)40:5<1270::AID-JCLP2270400526>3.0.CO;2-7
10.1093/cercor/bhq147
10.1073/pnas.1210984110
10.1001/archpsyc.61.7.705
10.1523/JNEUROSCI.17-19-07503.1997
10.1016/S0306-4522(02)00652-8
10.1016/j.neuint.2006.01.020
10.1503/jpn.130242
10.1038/mp.2012.194
10.1177/1073191114548873
10.1523/JNEUROSCI.17-08-02921.1997
10.1016/j.pnpbp.2013.06.010
10.1016/j.pnpbp.2006.04.022
10.1016/j.biopsych.2011.11.006
10.1176/appi.ajp.2011.09111607
10.1038/nn.4028
10.1192/bjp.134.4.382
10.1146/annurev-med-053013-062946
10.1074/jbc.M300792200
10.1002/da.22501
10.1016/j.nucmedbio.2013.09.008
10.1007/s00259-010-1723-7
10.1016/j.pbb.2005.06.015
10.1038/tp.2013.46
10.1177/0271678X16673646
10.1117/12.812170
ContentType Journal Article
Copyright Macmillan Publishers Limited, part of Springer Nature. 2018
COPYRIGHT 2018 Nature Publishing Group
Copyright Nature Publishing Group Apr 2018
Copyright_xml – notice: Macmillan Publishers Limited, part of Springer Nature. 2018
– notice: COPYRIGHT 2018 Nature Publishing Group
– notice: Copyright Nature Publishing Group Apr 2018
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
88G
8AO
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2M
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
5PM
DOI 10.1038/mp.2017.58
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Proquest Medical Database
Psychology Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
DatabaseTitleList MEDLINE


ProQuest One Psychology
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-5578
EndPage 832
ExternalDocumentID PMC5636649
A531833451
28397841
10_1038_mp_2017_58
Genre Research Support, U.S. Gov't, Non-P.H.S
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIMH NIH HHS
  grantid: K01 MH092681
– fundername: NIMH NIH HHS
  grantid: K23 MH101498
– fundername: NIMH NIH HHS
  grantid: R01 MH104512
– fundername: NIMH NIH HHS
  grantid: K01 MH091354
GroupedDBID ---
-Q-
0R~
123
29M
2WC
36B
39C
3V.
4.4
406
53G
70F
7X7
88E
8AO
8FI
8FJ
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAYZH
AAZLF
ABAKF
ABAWZ
ABDBF
ABIVO
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFS
ACKTT
ACPRK
ACRQY
ACUHS
ACZOJ
ADBBV
ADHDB
AEFQL
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFKRA
AFRAH
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AIGIU
AILAN
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
AXYYD
AZQEC
B0M
BAWUL
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
DIK
DNIVK
DPUIP
DU5
DWQXO
E3Z
EAD
EAP
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EMOBN
EPL
EPS
ESX
F5P
FDQFY
FEDTE
FERAY
FIGPU
FIZPM
FSGXE
FYUFA
GNUQQ
HCIFZ
HMCUK
HVGLF
HZ~
IAO
IHR
INH
INR
IPY
ITC
IWAJR
JSO
JZLTJ
KQ8
M1P
M2M
M7P
NAO
NQJWS
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
PSYQQ
Q2X
RNS
RNT
RNTTT
ROL
SNX
SNYQT
SOHCF
SOJ
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
TUS
UKHRP
~8M
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
AEZWR
AFDZB
AFHIU
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
AEIIB
PMFND
7TK
7XB
8FE
8FH
8FK
K9.
LK8
PKEHL
PQEST
PQUKI
PRINS
Q9U
5PM
ID FETCH-LOGICAL-c440t-be3f834f943bb70e79b120cd5f028efa5736f7fd356c01c532fdd634513df40b3
IEDL.DBID 7X7
ISSN 1359-4184
IngestDate Thu Aug 21 18:32:44 EDT 2025
Fri Jul 25 08:57:02 EDT 2025
Tue Jun 17 21:33:44 EDT 2025
Tue Jun 10 20:50:59 EDT 2025
Mon Jul 21 05:53:19 EDT 2025
Tue Jul 01 00:21:48 EDT 2025
Thu Apr 24 22:58:04 EDT 2025
Fri Feb 21 02:39:27 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c440t-be3f834f943bb70e79b120cd5f028efa5736f7fd356c01c532fdd634513df40b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ORCID 0000-0003-2117-9321
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC5636649
PMID 28397841
PQID 2016511942
PQPubID 44096
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5636649
proquest_journals_2016511942
gale_infotracmisc_A531833451
gale_infotracacademiconefile_A531833451
pubmed_primary_28397841
crossref_primary_10_1038_mp_2017_58
crossref_citationtrail_10_1038_mp_2017_58
springer_journals_10_1038_mp_2017_58
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-04-01
PublicationDateYYYYMMDD 2018-04-01
PublicationDate_xml – month: 04
  year: 2018
  text: 2018-04-01
  day: 01
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
– name: New York
PublicationTitle Molecular psychiatry
PublicationTitleAbbrev Mol Psychiatry
PublicationTitleAlternate Mol Psychiatry
PublicationYear 2018
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Page, Khidir, Pain, Barrier, Fauconneau, Guillard (CR75) 2006; 49
Krystal, Sanacora, Duman (CR6) 2013; 73
DeLorenzo, Kumar, Mann, Parsey (CR46) 2011; 31
Parker, Flint, Bosworth, Pieper, Steffens (CR52) 2003; 18
Abdallah, Adams, Kelmendi, Esterlis, Sanacora, Krystal (CR30) 2016; 33
Ametamey, Kessler, Honer, Wyss, Buck, Hintermann (CR41) 2006; 47
Hou, Klann (CR76) 2004; 24
Berman, Cappiello, Anand, Oren, Heninger, Charney (CR29) 2000; 47
DeLorenzo, Milak, Brennan, Kumar, Mann, Parsey (CR45) 2011; 38
Vollenweider, Leenders, Scharfetter, Antonini, Maguire, Missimer (CR78) 1997; 7
Sistiaga, Herrero, Conquet, Sánchez-Prieto (CR15) 1998; 37
Quiroz, Tamburri, Deptula, Banken, Beyer, Rabbia (CR69) 2016; 73
Shigemoto, Kinoshita, Wada, Nomura, Ohishi, Takada (CR17) 1997; 17
Hubert, Paquet, Smith (CR19) 2001; 21
Fontanez-Nuin, Santini, Quirk, Porter (CR71) 2011; 21
Matosin, Fernandez-Enright, Frank, Deng, Wong, Huang (CR27) 2014; 39
Pałucha, Brański, Szewczyk, Wierońska, Kłak, Pilc (CR66) 2005; 81
López-Bendito, Shigemoto, Fairén, Luján (CR20) 2002; 12
Kågedal, Cselényi, Nyberg, Raboisson, Ståhle, Stenkrona (CR63) 2013; 82
Abdallah, Sanacora, Duman, Krystal (CR64) 2015; 66
O'Malley, Jong, Gonchar, Burkhalter, Romano (CR21) 2003; 278
Deschwanden, Karolewicz, Feyissa, Treyer, Ametamey, Johayem (CR26) 2011; 168
Rusjan, Wilson, Bloomfield, Vitcu, Meyer, Houle (CR42) 2011; 31
CR2
Akkus, Ametamey, Treyer, Burger, Johayem, Umbricht (CR80) 2013; 110
Luykx, Laban, Heuvel, Boks, Mandl, Kahn (CR13) 2012; 36
Norcross, Guadagnoli, Prochaska (CR36) 1984; 40
CR9
CR47
Patel, Hamill, Connolly, Jagoda, Li, Gibson (CR49) 2007; 34
Sanacora, Gueorguieva, Epperson, Wu, Appel, Rothman (CR10) 2004; 61
Mora, Lara-García, Jacobsen, Vázquez-García, Crespo-Ramírez, Flores-Gracia (CR74) 2006; 23
Duman, Aghajanian, Sanacora, Krystal (CR56) 2016; 22
Krystal, Mathew, D'Souza, Garakani, Gunduz-Bruce, Charney (CR5) 2010; 24
Sandiego, Nabulsi, Lin, Labaree, Najafzadeh, Huang (CR37) 2013; 67
Breier, Malhotra, Pinals, Weisenfeld, Pickar (CR77) 1997; 154
DeLorenzo, Kumar, Mann, Parsey (CR60) 2011; 31
Kawamura, Yamasaki, Kumata, Furutsuka, Takei, Wakizaka (CR38) 2014; 41
Huang, Chen (CR53) 2015; 22
Bartolomeis, Sarappa, Buonaguro, Marmo, Eramo, Tomasetti (CR59) 2013; 46
Bremner, Krystal, Putnam, Southwick, Marmar, Charney (CR35) 1999; 11
Pałucha-Poniewiera, Wierońska, Brański, Burnat, Chruścicka, Pilc (CR68) 2013; 65
Wieronska, Branski, Szewczyk, Palucha, Papp, Gruca (CR24) 2001; 53
Kovacevic, Skelin, Minuzzi, Rosa-Neto, Diksic (CR23) 2012; 87
McClintock, Husain, Wisniewski, Nierenberg, Stewart, Trivedi (CR3) 2011; 31
Manahan-Vaughan, Braunewell (CR16) 1999; 96
Anticevic, Gancsos, Murray, Repovs, Driesen, Ennis (CR39) 2012; 109
Chowdhury, Behar, Cho, Thomas, Rothman, Sanacora (CR31) 2012; 71
Sanacora, Zarate, Krystal, Manji (CR7) 2008; 7
Iijima, Fukumoto, Chaki (CR70) 2012; 235
Moghaddam, Adams, Verma, Daly (CR54) 1997; 17
Miyake, Skinbjerg, Easwaramoorthy, Kumar, Girgis, Xu (CR12) 2011; 69
Tatarczyńska, Klodzińska, Chojnacka-Wójcik, Palucha, Gasparini, Kuhn (CR67) 2001; 132
Molina-Hernández, Tellez-Alcántara, Pérez-García, Olivera-Lopez, Jaramillo (CR73) 2006; 30
Hashimoto, Sawa, Iyo (CR8) 2007; 62
DeLorenzo, DellaGioia, Bloch, Sanacora, Nabulsi, Abdallah (CR11) 2015; 77
Wu, Ogden, Mann, Parsey (CR44) 2007; 48
Treyer, Streffer, Wyss, Bettio, Ametamey, Fischer (CR48) 2007; 48
Montgomery, Asberg (CR33) 1979; 134
Beck, Ward, Mendelsohn, Erbaugh (CR34) 1961; 4
Innis, Cunningham, Delforge, Fujita, Gjedde, Gunn (CR50) 2007; 27
Rowland, Beason-Held, Tamminga, Holcomb (CR79) 2010; 208
Fatemi, Folsom, Rooney, Thuras (CR25) 2013; 3
Driesen, McCarthy, Bhagwagar, Bloch, Calhoun, D'Souza (CR40) 2013; 18
Gallezot, Nabulsi, Neumeister, Planeta-Wilson, Williams, Singhal (CR43) 2010; 30
Zisook, Ganadjian, Moutier, Prather, Rao (CR4) 2008; 69
Kim, Lee, Lee, Han, Lee, Sohn (CR57) 2015; 35
Smialowska, Szewczyk, Branski, Wieronska, Palucha, Bajkowska (CR28) 2002; 42
Shin, Kwon, Kang, Kwon, Oh, Choi (CR22) 2015; 18
Chowdhury, Zhang, Thomas, Banasr, Ma, Pittman (CR32) 2016; 22
Li, Lee, Liu, Banasr, Dwyer, Iwata (CR65) 2010; 329
Takumi, Matsubara, Rinvik, Ottersen (CR18) 1999; 868
CR61
Attwell, Buchan, Charpak, Lauritzen, Macvicar, Newman (CR62) 2010; 468
Zanos, Moaddel, Morris, Georgiou, Fischell, Elmer (CR55) 2016; 533
(CR1) 2015; 386
Hirvonen, Johansson, Teras, Oikonen, Lumme, Virsu (CR51) 2008; 28
Lorrain, Baccei, Bristow, Anderson, Varney (CR58) 2003; 117
Hasler, Veen, Tumonis, Meyers, Shen, Drevets (CR14) 2007; 64
Chen, Liu, Ali, Gui, Hou, Fan (CR72) 2011; 84
D Fontanez-Nuin (BFmp201758_CR71) 2011; 21
J Krystal (BFmp201758_CR5) 2010; 24
C DeLorenzo (BFmp201758_CR11) 2015; 77
SA Montgomery (BFmp201758_CR33) 1979; 134
D Lorrain (BFmp201758_CR58) 2003; 117
D Attwell (BFmp201758_CR62) 2010; 468
A Deschwanden (BFmp201758_CR26) 2011; 168
G Hasler (BFmp201758_CR14) 2007; 64
L Hou (BFmp201758_CR76) 2004; 24
G Sanacora (BFmp201758_CR10) 2004; 61
M Smialowska (BFmp201758_CR28) 2002; 42
S Zisook (BFmp201758_CR4) 2008; 69
J Luykx (BFmp201758_CR13) 2012; 36
Y Takumi (BFmp201758_CR18) 1999; 868
BFmp201758_CR47
G Page (BFmp201758_CR75) 2006; 49
G Chowdhury (BFmp201758_CR31) 2012; 71
S Beck (BFmp201758_CR34) 1961; 4
S McClintock (BFmp201758_CR3) 2011; 31
G Sanacora (BFmp201758_CR7) 2008; 7
R Berman (BFmp201758_CR29) 2000; 47
R Parker (BFmp201758_CR52) 2003; 18
A Sistiaga (BFmp201758_CR15) 1998; 37
G López-Bendito (BFmp201758_CR20) 2002; 12
SH Fatemi (BFmp201758_CR25) 2013; 3
PM Rusjan (BFmp201758_CR42) 2011; 31
F Akkus (BFmp201758_CR80) 2013; 110
A Anticevic (BFmp201758_CR39) 2012; 109
S Wu (BFmp201758_CR44) 2007; 48
G Chowdhury (BFmp201758_CR32) 2016; 22
MPdl Mora (BFmp201758_CR74) 2006; 23
B Moghaddam (BFmp201758_CR54) 1997; 17
A Pałucha (BFmp201758_CR66) 2005; 81
BFmp201758_CR2
F Vollenweider (BFmp201758_CR78) 1997; 7
L Rowland (BFmp201758_CR79) 2010; 208
H Kim (BFmp201758_CR57) 2015; 35
D Manahan-Vaughan (BFmp201758_CR16) 1999; 96
G Hubert (BFmp201758_CR19) 2001; 21
Ad Bartolomeis (BFmp201758_CR59) 2013; 46
E Tatarczyńska (BFmp201758_CR67) 2001; 132
JA Quiroz (BFmp201758_CR69) 2016; 73
BFmp201758_CR9
C DeLorenzo (BFmp201758_CR46) 2011; 31
A Pałucha-Poniewiera (BFmp201758_CR68) 2013; 65
M Iijima (BFmp201758_CR70) 2012; 235
M Molina-Hernández (BFmp201758_CR73) 2006; 30
Global Burden of Disease Study Collaborators (BFmp201758_CR1) 2015; 386
NR Driesen (BFmp201758_CR40) 2013; 18
T Kovacevic (BFmp201758_CR23) 2012; 87
C DeLorenzo (BFmp201758_CR60) 2011; 31
R Shigemoto (BFmp201758_CR17) 1997; 17
J Krystal (BFmp201758_CR6) 2013; 73
S Ametamey (BFmp201758_CR41) 2006; 47
N Miyake (BFmp201758_CR12) 2011; 69
K Kawamura (BFmp201758_CR38) 2014; 41
K Hashimoto (BFmp201758_CR8) 2007; 62
CM Sandiego (BFmp201758_CR37) 2013; 67
C Abdallah (BFmp201758_CR64) 2015; 66
A Breier (BFmp201758_CR77) 1997; 154
C Huang (BFmp201758_CR53) 2015; 22
K O'Malley (BFmp201758_CR21) 2003; 278
C DeLorenzo (BFmp201758_CR45) 2011; 38
RB Innis (BFmp201758_CR50) 2007; 27
V Treyer (BFmp201758_CR48) 2007; 48
L Chen (BFmp201758_CR72) 2011; 84
JM Wieronska (BFmp201758_CR24) 2001; 53
N Matosin (BFmp201758_CR27) 2014; 39
J Hirvonen (BFmp201758_CR51) 2008; 28
S Patel (BFmp201758_CR49) 2007; 34
JD Gallezot (BFmp201758_CR43) 2010; 30
BFmp201758_CR61
P Zanos (BFmp201758_CR55) 2016; 533
C Abdallah (BFmp201758_CR30) 2016; 33
J Norcross (BFmp201758_CR36) 1984; 40
R Duman (BFmp201758_CR56) 2016; 22
S Shin (BFmp201758_CR22) 2015; 18
J Bremner (BFmp201758_CR35) 1999; 11
M Kågedal (BFmp201758_CR63) 2013; 82
N Li (BFmp201758_CR65) 2010; 329
References_xml – volume: 28
  start-page: 1059
  year: 2008
  end-page: 1069
  ident: CR51
  article-title: Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/sj.jcbfm.9600607
– volume: 7
  start-page: 9
  year: 1997
  end-page: 24
  ident: CR78
  article-title: Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose(FDG)
  publication-title: Eur Neuropsychopharmacol
  doi: 10.1016/S0924-977X(96)00039-9
– volume: 77
  start-page: 266
  year: 2015
  end-page: 275
  ident: CR11
  article-title: ketamine-induced changes in [11C]ABP688 binding to metabotropic glutamate receptor subtype 5
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2014.06.024
– volume: 96
  start-page: 8739
  year: 1999
  end-page: 8744
  ident: CR16
  article-title: Novelty acquisition is associated with induction of hippocampal long-term depression
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.96.15.8739
– volume: 24
  start-page: 6352
  year: 2004
  end-page: 6361
  ident: CR76
  article-title: Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.0995-04.2004
– volume: 27
  start-page: 1533
  year: 2007
  end-page: 1539
  ident: CR50
  article-title: Consensus nomenclature for imaging of reversibly binding radioligands
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/sj.jcbfm.9600493
– volume: 36
  start-page: 198
  year: 2012
  end-page: 205
  ident: CR13
  article-title: Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings
  publication-title: Neurosci Biobehav Rev
  doi: 10.1016/j.neubiorev.2011.05.014
– volume: 84
  start-page: 215
  year: 2011
  end-page: 223
  ident: CR72
  article-title: Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions
  publication-title: Brain Res Bull
  doi: 10.1016/j.brainresbull.2011.01.005
– volume: 48
  start-page: 1207
  year: 2007
  end-page: 1215
  ident: CR48
  article-title: Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.107.039578
– volume: 62
  start-page: 1310
  year: 2007
  end-page: 1316
  ident: CR8
  article-title: Increased levels of glutamate in brains from patients with mood disorders
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2007.03.017
– volume: 47
  start-page: 698
  year: 2006
  end-page: 705
  ident: CR41
  article-title: Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5
  publication-title: J Nucl Med
– volume: 31
  start-page: 1807
  year: 2011
  end-page: 1816
  ident: CR42
  article-title: Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2011.55
– volume: 65
  start-page: 1506
  year: 2013
  end-page: 1511
  ident: CR68
  article-title: Is the mGlu5 receptor a possible target for new antidepressant drugs?
  publication-title: Pharmacol Rep
  doi: 10.1016/S1734-1140(13)71511-1
– volume: 37
  start-page: 1485
  year: 1998
  end-page: 1492
  ident: CR15
  article-title: The metabotropic glutamate receptor 1 is not involved in the facilitation of glutamate release in cerebrocortical nerve terminals
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(98)00129-4
– volume: 208
  start-page: 575
  year: 2010
  end-page: 584
  ident: CR79
  article-title: The interactive effects of ketamine and nicotine on human cerebral blood flow
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-009-1758-2
– volume: 24
  start-page: 669
  year: 2010
  end-page: 693
  ident: CR5
  article-title: Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists
  publication-title: CNS Drugs
  doi: 10.2165/11533230-000000000-00000
– ident: CR61
– volume: 21
  start-page: 1838
  year: 2001
  end-page: 1847
  ident: CR19
  article-title: Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey substantia nigra
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.21-06-01838.2001
– volume: 329
  start-page: 959
  year: 2010
  end-page: 964
  ident: CR65
  article-title: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists
  publication-title: Science
  doi: 10.1126/science.1190287
– volume: 48
  start-page: 926
  year: 2007
  end-page: 931
  ident: CR44
  article-title: Optimal metabolite curve fitting for kinetic modeling of 11C-WAY-100635
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.106.038075
– volume: 31
  start-page: 2169
  year: 2011
  end-page: 2180
  ident: CR46
  article-title: variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2011.105
– volume: 23
  start-page: 2749
  year: 2006
  end-page: 2759
  ident: CR74
  article-title: Anxiolytic-like effects of the selective metabotropic glutamate receptor 5 antagonist MPEP after its intra-amygdaloid microinjection in three different non-conditioned rat models of anxiety
  publication-title: Eur J Neurosci
  doi: 10.1111/j.1460-9568.2006.04798.x
– volume: 69
  start-page: 822
  year: 2011
  end-page: 824
  ident: CR12
  article-title: Imaging changes in glutamate transmission with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2010.12.023
– volume: 35
  start-page: 6401
  year: 2015
  end-page: 6412
  ident: CR57
  article-title: Costimulation of AMPA and metabotropic glutamate receptors underlies phospholipase C activation by glutamate in hippocampus
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.4208-14.2015
– volume: 53
  start-page: 659
  year: 2001
  end-page: 662
  ident: CR24
  article-title: Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression
  publication-title: Pol J Pharmacol
– volume: 73
  start-page: 1133
  year: 2013
  end-page: 1141
  ident: CR6
  article-title: Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2013.03.026
– volume: 4
  start-page: 561
  year: 1961
  end-page: 571
  ident: CR34
  article-title: An inventory for measuring depression
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1961.01710120031004
– volume: 67
  start-page: 489
  year: 2013
  end-page: 501
  ident: CR37
  article-title: Studies of the metabotropic glutamate receptor 5 radioligand [(1)(1)C]ABP688 with N-acetylcysteine challenge in rhesus monkeys
  publication-title: Synapse
  doi: 10.1002/syn.21656
– volume: 11
  start-page: 125
  year: 1999
  end-page: 136
  ident: CR35
  article-title: Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)
  publication-title: J Trauma Stress
  doi: 10.1023/A:1024465317902
– volume: 468
  start-page: 232
  year: 2010
  end-page: 243
  ident: CR62
  article-title: Glial and neuronal control of brain blood flow
  publication-title: Nature
  doi: 10.1038/nature09613
– ident: CR9
– volume: 42
  start-page: 1016
  year: 2002
  end-page: 1023
  ident: CR28
  article-title: Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(02)00062-X
– volume: 22
  start-page: 120
  year: 2016
  end-page: 126
  ident: CR32
  article-title: Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2016.34
– volume: 87
  start-page: 406
  year: 2012
  end-page: 412
  ident: CR23
  article-title: Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study
  publication-title: Brain Res Bull
  doi: 10.1016/j.brainresbull.2012.01.010
– volume: 533
  start-page: 481
  year: 2016
  end-page: 486
  ident: CR55
  article-title: NMDAR inhibition-independent antidepressant actions of ketamine metabolites
  publication-title: Nature
  doi: 10.1038/nature17998
– volume: 30
  start-page: 196
  year: 2010
  end-page: 210
  ident: CR43
  article-title: Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2009.195
– volume: 235
  start-page: 287
  year: 2012
  end-page: 292
  ident: CR70
  article-title: Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test
  publication-title: Behav Brain Res
  doi: 10.1016/j.bbr.2012.08.016
– volume: 12
  start-page: 625
  year: 2002
  end-page: 638
  ident: CR20
  article-title: Differential distribution of group I metabotropic glutamate receptors during rat cortical development
  publication-title: Cereb Cortex
  doi: 10.1093/cercor/12.6.625
– volume: 73
  start-page: 675
  year: 2016
  end-page: 684
  ident: CR69
  article-title: Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2016.0838
– volume: 109
  start-page: 16720
  year: 2012
  end-page: 16725
  ident: CR39
  article-title: NMDA receptor function in large-scale anti-correlated neural systems with implications for cognition and schizophrenia
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1208494109
– ident: CR47
– volume: 132
  start-page: 1423
  year: 2001
  end-page: 1430
  ident: CR67
  article-title: Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0703923
– volume: 868
  start-page: 474
  year: 1999
  end-page: 482
  ident: CR18
  article-title: The arrangement of glutamate receptors in excitatory synapses
  publication-title: Ann NY Acad Sci
  doi: 10.1111/j.1749-6632.1999.tb11316.x
– volume: 154
  start-page: 805
  year: 1997
  end-page: 811
  ident: CR77
  article-title: Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.154.6.805
– volume: 7
  start-page: 426
  year: 2008
  end-page: 437
  ident: CR7
  article-title: Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd2462
– volume: 31
  start-page: 2169
  year: 2011
  end-page: 2180
  ident: CR60
  article-title: variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [ C]ABP688
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2011.105
– ident: CR2
– volume: 34
  start-page: 1009
  year: 2007
  end-page: 1017
  ident: CR49
  article-title: Species differences in mGluR5 binding sites in mammalian central nervous system determined using binding with [18F]F-PEB
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2007.07.009
– volume: 386
  start-page: 743
  year: 2015
  end-page: 800
  ident: CR1
  article-title: Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)60692-4
– volume: 69
  start-page: 1184
  year: 2008
  end-page: 1185
  ident: CR4
  article-title: Sequenced Treatment Alternatives to Relieve Depression (STAR*D): lessons learned
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v69n0719
– volume: 82
  start-page: 160
  year: 2013
  end-page: 169
  ident: CR63
  article-title: A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 - estimating occupancy in the absence of a reference region
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2013.05.006
– volume: 31
  start-page: 180
  year: 2011
  end-page: 186
  ident: CR3
  article-title: Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/JCP.0b013e31820ebd2c
– volume: 22
  start-page: 238
  year: 2016
  end-page: 249
  ident: CR56
  article-title: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
  publication-title: Nat Med
  doi: 10.1038/nm.4050
– volume: 18
  start-page: 73
  year: 2003
  end-page: 77
  ident: CR52
  article-title: A three-factor analytic model of the MADRS in geriatric depression
  publication-title: Int J Geriatr Psychiatry
  doi: 10.1002/gps.776
– volume: 47
  start-page: 351
  year: 2000
  end-page: 354
  ident: CR29
  article-title: Antidepressant effects of ketamine in depressed patients
  publication-title: Biol Psychiatry
  doi: 10.1016/S0006-3223(99)00230-9
– volume: 64
  start-page: 193
  year: 2007
  end-page: 200
  ident: CR14
  article-title: Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.64.2.193
– volume: 40
  start-page: 1270
  year: 1984
  end-page: 1277
  ident: CR36
  article-title: Factor structure of the profile of mood states (POMs), two partial replications
  publication-title: J Clin Psychol
  doi: 10.1002/1097-4679(198409)40:5<1270::AID-JCLP2270400526>3.0.CO;2-7
– volume: 21
  start-page: 727
  year: 2011
  end-page: 735
  ident: CR71
  article-title: Memory for fear extinction requires mGluR5-mediated activation of infralimbic neurons
  publication-title: Cereb Cortex
  doi: 10.1093/cercor/bhq147
– volume: 110
  start-page: 334
  year: 2013
  ident: CR80
  article-title: Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1210984110
– volume: 61
  start-page: 705
  year: 2004
  end-page: 713
  ident: CR10
  article-title: Subtype-specific alterations of GABA and glutamate in major depression
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.61.7.705
– volume: 17
  start-page: 7503
  year: 1997
  end-page: 7522
  ident: CR17
  article-title: Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.17-19-07503.1997
– volume: 117
  start-page: 697
  year: 2003
  end-page: 706
  ident: CR58
  article-title: Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268
  publication-title: Neuroscience
  doi: 10.1016/S0306-4522(02)00652-8
– volume: 49
  start-page: 413
  year: 2006
  end-page: 421
  ident: CR75
  article-title: Group I metabotropic glutamate receptors activate the p70S6 kinase via both mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK 1/2) signaling pathways in rat striatal and hippocampal synaptoneurosomes
  publication-title: Neurochem Int
  doi: 10.1016/j.neuint.2006.01.020
– volume: 39
  start-page: 407
  year: 2014
  end-page: 416
  ident: CR27
  article-title: Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics
  publication-title: J Psychiatry Neurosci
  doi: 10.1503/jpn.130242
– volume: 18
  start-page: 1199
  year: 2013
  end-page: 1204
  ident: CR40
  article-title: Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2012.194
– volume: 22
  start-page: 459
  year: 2015
  end-page: 472
  ident: CR53
  article-title: Meta-analysis of the factor structures of the Beck Depression Inventory-II
  publication-title: Assessment
  doi: 10.1177/1073191114548873
– volume: 17
  start-page: 2921
  year: 1997
  end-page: 2927
  ident: CR54
  article-title: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.17-08-02921.1997
– volume: 46
  start-page: 1
  year: 2013
  end-page: 12
  ident: CR59
  article-title: Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
  doi: 10.1016/j.pnpbp.2013.06.010
– volume: 30
  start-page: 1129
  year: 2006
  end-page: 1135
  ident: CR73
  article-title: Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
  doi: 10.1016/j.pnpbp.2006.04.022
– volume: 71
  start-page: 1022
  year: 2012
  end-page: 1025
  ident: CR31
  article-title: ¹H-[¹ C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2011.11.006
– volume: 168
  start-page: 727
  year: 2011
  end-page: 734
  ident: CR26
  article-title: Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2011.09111607
– volume: 18
  start-page: 1017
  year: 2015
  end-page: 1024
  ident: CR22
  article-title: mGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress
  publication-title: Nat Neurosci
  doi: 10.1038/nn.4028
– volume: 134
  start-page: 382
  year: 1979
  end-page: 389
  ident: CR33
  article-title: A new depression scale designed to be sensitive to change
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.134.4.382
– volume: 66
  start-page: 509
  year: 2015
  end-page: 523
  ident: CR64
  article-title: Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics
  publication-title: Annu Rev Med
  doi: 10.1146/annurev-med-053013-062946
– volume: 278
  start-page: 28210
  year: 2003
  end-page: 28219
  ident: CR21
  article-title: Activation of metabotropic glutamate receptor mGlu5 on nuclear membranes mediates intranuclear Ca2+ changes in heterologous cell types and neurons
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M300792200
– volume: 33
  start-page: 689
  year: 2016
  end-page: 697
  ident: CR30
  article-title: Ketamine's mechanism of action: a path to rapid-acting antidepressants
  publication-title: Depress Anxiety
  doi: 10.1002/da.22501
– volume: 41
  start-page: 17
  year: 2014
  end-page: 23
  ident: CR38
  article-title: Binding potential of (E)-[(11)C]ABP688 to metabotropic glutamate receptor subtype 5 is decreased by the inclusion of its (11)C-labelled Z-isomer
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2013.09.008
– volume: 38
  start-page: 1083
  year: 2011
  end-page: 1094
  ident: CR45
  article-title: positron emission tomography imaging with [(11)C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-010-1723-7
– volume: 81
  start-page: 901
  year: 2005
  end-page: 906
  ident: CR66
  article-title: Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/j.pbb.2005.06.015
– volume: 3
  start-page: e271
  year: 2013
  ident: CR25
  article-title: mRNA and protein expression for novel GABAA receptors theta and rho2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway
  publication-title: Transl Psychiatry
  doi: 10.1038/tp.2013.46
– volume: 329
  start-page: 959
  year: 2010
  ident: BFmp201758_CR65
  publication-title: Science
  doi: 10.1126/science.1190287
– volume: 4
  start-page: 561
  year: 1961
  ident: BFmp201758_CR34
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1961.01710120031004
– volume: 71
  start-page: 1022
  year: 2012
  ident: BFmp201758_CR31
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2011.11.006
– volume: 69
  start-page: 822
  year: 2011
  ident: BFmp201758_CR12
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2010.12.023
– volume: 154
  start-page: 805
  year: 1997
  ident: BFmp201758_CR77
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.154.6.805
– volume: 18
  start-page: 1017
  year: 2015
  ident: BFmp201758_CR22
  publication-title: Nat Neurosci
  doi: 10.1038/nn.4028
– volume: 66
  start-page: 509
  year: 2015
  ident: BFmp201758_CR64
  publication-title: Annu Rev Med
  doi: 10.1146/annurev-med-053013-062946
– volume: 134
  start-page: 382
  year: 1979
  ident: BFmp201758_CR33
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.134.4.382
– volume: 7
  start-page: 9
  year: 1997
  ident: BFmp201758_CR78
  publication-title: Eur Neuropsychopharmacol
  doi: 10.1016/S0924-977X(96)00039-9
– volume: 81
  start-page: 901
  year: 2005
  ident: BFmp201758_CR66
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/j.pbb.2005.06.015
– volume: 468
  start-page: 232
  year: 2010
  ident: BFmp201758_CR62
  publication-title: Nature
  doi: 10.1038/nature09613
– volume: 47
  start-page: 351
  year: 2000
  ident: BFmp201758_CR29
  publication-title: Biol Psychiatry
  doi: 10.1016/S0006-3223(99)00230-9
– volume: 82
  start-page: 160
  year: 2013
  ident: BFmp201758_CR63
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2013.05.006
– volume: 62
  start-page: 1310
  year: 2007
  ident: BFmp201758_CR8
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2007.03.017
– volume: 3
  start-page: e271
  year: 2013
  ident: BFmp201758_CR25
  publication-title: Transl Psychiatry
  doi: 10.1038/tp.2013.46
– volume: 17
  start-page: 7503
  year: 1997
  ident: BFmp201758_CR17
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.17-19-07503.1997
– volume: 533
  start-page: 481
  year: 2016
  ident: BFmp201758_CR55
  publication-title: Nature
  doi: 10.1038/nature17998
– volume: 77
  start-page: 266
  year: 2015
  ident: BFmp201758_CR11
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2014.06.024
– volume: 109
  start-page: 16720
  year: 2012
  ident: BFmp201758_CR39
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1208494109
– volume: 87
  start-page: 406
  year: 2012
  ident: BFmp201758_CR23
  publication-title: Brain Res Bull
  doi: 10.1016/j.brainresbull.2012.01.010
– volume: 42
  start-page: 1016
  year: 2002
  ident: BFmp201758_CR28
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(02)00062-X
– volume: 7
  start-page: 426
  year: 2008
  ident: BFmp201758_CR7
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd2462
– volume: 22
  start-page: 120
  year: 2016
  ident: BFmp201758_CR32
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2016.34
– volume: 235
  start-page: 287
  year: 2012
  ident: BFmp201758_CR70
  publication-title: Behav Brain Res
  doi: 10.1016/j.bbr.2012.08.016
– volume: 30
  start-page: 196
  year: 2010
  ident: BFmp201758_CR43
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2009.195
– volume: 278
  start-page: 28210
  year: 2003
  ident: BFmp201758_CR21
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M300792200
– volume: 34
  start-page: 1009
  year: 2007
  ident: BFmp201758_CR49
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2007.07.009
– volume: 27
  start-page: 1533
  year: 2007
  ident: BFmp201758_CR50
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/sj.jcbfm.9600493
– volume: 96
  start-page: 8739
  year: 1999
  ident: BFmp201758_CR16
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.96.15.8739
– volume: 23
  start-page: 2749
  year: 2006
  ident: BFmp201758_CR74
  publication-title: Eur J Neurosci
  doi: 10.1111/j.1460-9568.2006.04798.x
– volume: 65
  start-page: 1506
  year: 2013
  ident: BFmp201758_CR68
  publication-title: Pharmacol Rep
  doi: 10.1016/S1734-1140(13)71511-1
– volume: 110
  start-page: 334
  year: 2013
  ident: BFmp201758_CR80
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1210984110
– ident: BFmp201758_CR61
  doi: 10.1177/0271678X16673646
– volume: 37
  start-page: 1485
  year: 1998
  ident: BFmp201758_CR15
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(98)00129-4
– volume: 21
  start-page: 1838
  year: 2001
  ident: BFmp201758_CR19
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.21-06-01838.2001
– volume: 49
  start-page: 413
  year: 2006
  ident: BFmp201758_CR75
  publication-title: Neurochem Int
  doi: 10.1016/j.neuint.2006.01.020
– volume: 31
  start-page: 1807
  year: 2011
  ident: BFmp201758_CR42
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2011.55
– volume: 46
  start-page: 1
  year: 2013
  ident: BFmp201758_CR59
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
  doi: 10.1016/j.pnpbp.2013.06.010
– volume: 48
  start-page: 1207
  year: 2007
  ident: BFmp201758_CR48
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.107.039578
– volume: 17
  start-page: 2921
  year: 1997
  ident: BFmp201758_CR54
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.17-08-02921.1997
– ident: BFmp201758_CR47
  doi: 10.1117/12.812170
– volume: 386
  start-page: 743
  year: 2015
  ident: BFmp201758_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)60692-4
– volume: 30
  start-page: 1129
  year: 2006
  ident: BFmp201758_CR73
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
  doi: 10.1016/j.pnpbp.2006.04.022
– volume: 208
  start-page: 575
  year: 2010
  ident: BFmp201758_CR79
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-009-1758-2
– volume: 64
  start-page: 193
  year: 2007
  ident: BFmp201758_CR14
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.64.2.193
– volume: 39
  start-page: 407
  year: 2014
  ident: BFmp201758_CR27
  publication-title: J Psychiatry Neurosci
  doi: 10.1503/jpn.130242
– volume: 40
  start-page: 1270
  year: 1984
  ident: BFmp201758_CR36
  publication-title: J Clin Psychol
  doi: 10.1002/1097-4679(198409)40:5<1270::AID-JCLP2270400526>3.0.CO;2-7
– volume: 18
  start-page: 73
  year: 2003
  ident: BFmp201758_CR52
  publication-title: Int J Geriatr Psychiatry
  doi: 10.1002/gps.776
– volume: 21
  start-page: 727
  year: 2011
  ident: BFmp201758_CR71
  publication-title: Cereb Cortex
  doi: 10.1093/cercor/bhq147
– volume: 31
  start-page: 2169
  year: 2011
  ident: BFmp201758_CR46
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2011.105
– volume: 31
  start-page: 2169
  year: 2011
  ident: BFmp201758_CR60
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2011.105
– volume: 28
  start-page: 1059
  year: 2008
  ident: BFmp201758_CR51
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/sj.jcbfm.9600607
– volume: 36
  start-page: 198
  year: 2012
  ident: BFmp201758_CR13
  publication-title: Neurosci Biobehav Rev
  doi: 10.1016/j.neubiorev.2011.05.014
– volume: 12
  start-page: 625
  year: 2002
  ident: BFmp201758_CR20
  publication-title: Cereb Cortex
  doi: 10.1093/cercor/12.6.625
– volume: 22
  start-page: 459
  year: 2015
  ident: BFmp201758_CR53
  publication-title: Assessment
  doi: 10.1177/1073191114548873
– volume: 61
  start-page: 705
  year: 2004
  ident: BFmp201758_CR10
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.61.7.705
– volume: 132
  start-page: 1423
  year: 2001
  ident: BFmp201758_CR67
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0703923
– ident: BFmp201758_CR9
– volume: 24
  start-page: 669
  year: 2010
  ident: BFmp201758_CR5
  publication-title: CNS Drugs
  doi: 10.2165/11533230-000000000-00000
– volume: 38
  start-page: 1083
  year: 2011
  ident: BFmp201758_CR45
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-010-1723-7
– volume: 22
  start-page: 238
  year: 2016
  ident: BFmp201758_CR56
  publication-title: Nat Med
  doi: 10.1038/nm.4050
– volume: 11
  start-page: 125
  year: 1999
  ident: BFmp201758_CR35
  publication-title: J Trauma Stress
  doi: 10.1023/A:1024465317902
– volume: 69
  start-page: 1184
  year: 2008
  ident: BFmp201758_CR4
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v69n0719
– volume: 67
  start-page: 489
  year: 2013
  ident: BFmp201758_CR37
  publication-title: Synapse
  doi: 10.1002/syn.21656
– volume: 73
  start-page: 1133
  year: 2013
  ident: BFmp201758_CR6
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2013.03.026
– volume: 53
  start-page: 659
  year: 2001
  ident: BFmp201758_CR24
  publication-title: Pol J Pharmacol
– volume: 31
  start-page: 180
  year: 2011
  ident: BFmp201758_CR3
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/JCP.0b013e31820ebd2c
– volume: 24
  start-page: 6352
  year: 2004
  ident: BFmp201758_CR76
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.0995-04.2004
– volume: 73
  start-page: 675
  year: 2016
  ident: BFmp201758_CR69
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2016.0838
– volume: 48
  start-page: 926
  year: 2007
  ident: BFmp201758_CR44
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.106.038075
– ident: BFmp201758_CR2
– volume: 18
  start-page: 1199
  year: 2013
  ident: BFmp201758_CR40
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2012.194
– volume: 47
  start-page: 698
  year: 2006
  ident: BFmp201758_CR41
  publication-title: J Nucl Med
– volume: 168
  start-page: 727
  year: 2011
  ident: BFmp201758_CR26
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2011.09111607
– volume: 41
  start-page: 17
  year: 2014
  ident: BFmp201758_CR38
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2013.09.008
– volume: 868
  start-page: 474
  year: 1999
  ident: BFmp201758_CR18
  publication-title: Ann NY Acad Sci
  doi: 10.1111/j.1749-6632.1999.tb11316.x
– volume: 35
  start-page: 6401
  year: 2015
  ident: BFmp201758_CR57
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.4208-14.2015
– volume: 117
  start-page: 697
  year: 2003
  ident: BFmp201758_CR58
  publication-title: Neuroscience
  doi: 10.1016/S0306-4522(02)00652-8
– volume: 84
  start-page: 215
  year: 2011
  ident: BFmp201758_CR72
  publication-title: Brain Res Bull
  doi: 10.1016/j.brainresbull.2011.01.005
– volume: 33
  start-page: 689
  year: 2016
  ident: BFmp201758_CR30
  publication-title: Depress Anxiety
  doi: 10.1002/da.22501
SSID ssj0014765
Score 2.5596814
Snippet The mechanisms of action of the rapid antidepressant effects of ketamine, an N -methyl- D -aspartate glutamate receptor antagonist, have not been fully...
The mechanisms of action of the rapid antidepressant effects of ketamine, an N-methyl-D-aspartate glutamate receptor antagonist, have not been fully...
The mechanisms of action of the rapid antidepressant effects of ketamine, an NMDA glutamate receptor antagonist, have not been fully elucidated. This study...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 824
SubjectTerms 631/337
631/378
Adult
Antidepressants
Antidepressive Agents - pharmacology
Anxiety disorders
Behavioral Sciences
Biological Psychology
Biomedical engineering
Brain - metabolism
Carbon Radioisotopes
Case-Control Studies
Comparative analysis
Depression - diagnostic imaging
Depressive Disorder, Major - diagnostic imaging
Depressive Disorder, Major - metabolism
Dosage and administration
Drug abuse
Excitatory Amino Acid Antagonists - pharmacology
Female
Glutamatergic transmission
Glutamic Acid - metabolism
Glutamic acid receptors (metabotropic)
Health care
Humans
Internalization
Intravenous administration
Ketamine
Ketamine - metabolism
Ketamine - pharmacology
Ligands
Major depressive disorder
Male
Medicine
Medicine & Public Health
Mental depression
Mental disorders
Metabotropic glutamate receptors
Metabotropic receptors
N-Methyl-D-aspartic acid receptors
Neurosciences
original-article
Pharmacotherapy
Positron emission tomography
Positron-Emission Tomography - methods
Proteins
Psychiatry
Radiation
Receptor, Metabotropic Glutamate 5 - drug effects
Receptor, Metabotropic Glutamate 5 - metabolism
Spectrum analysis
Substance abuse treatment
Tomography
Title Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression
URI https://link.springer.com/article/10.1038/mp.2017.58
https://www.ncbi.nlm.nih.gov/pubmed/28397841
https://www.proquest.com/docview/2016511942
https://pubmed.ncbi.nlm.nih.gov/PMC5636649
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ta9swEBZby2BfRvdar10RrDD2wVsUSba8LyMpycrGQigtBMYwsl6YIXazxh30d-wPTyfLbpONgcEWOiSZO0l3utNzCB1nCTdWUxkXTMuYKT6Ey8okLmzm7CFaKOIP3L7OktML9nnBF-HAbR3CKrs10S_U-lLBGbkz0kkCPi82_Lj6GUPWKPCuhhQa99EuQJdBSFe66A0uwlKfSpJQDt5OwTp4UireV4BVSdJ3kOr9zoa0vSzf2Ze2Yya3HKd-P5ruoUdBkcSjlvOP0T1TP0EP2tSSN0_R7y-mkZVTIWNndDv2aXwFIK3ABlzWuPq0vD7jWP6S5bJF6r7B5RrLwCxHDge0WNbuacoQLus-XSs-ptZ8gLpvhJx8H43niRCuqPF8co7Lyuc9wh63FrrqY23rZ-hiOjk_OY1DAoZYMTZo4sJQKyizGaNFkQ5MmhVkOFCaW6eVGCt5ShObOlbzRA2I4nRotU4o44RqywYFfY526sva7CNsDRHSWoAXNAzUxsJYoblJDXhyDY_Q244LuQro5JAkY5l7LzkVebXKgWM5FxF63dOuWkyOf1K9AWbmMFFdS0qG-wZuPAB5lY84LGcw2AgdblC6CaY2qztxyMMEX-e34hihF61k9GNxGlsG7twIpRsy0xMApPdmTV3-8NDePKFJwrIIHXfSddvl37_48v8jO0APXUG0cUaHaKe5ujavnArVFEd-nhyh3dF0PJ6593gym5_9ARn-HqE
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1taxNBEB5qiugX8d3TqgtWxA9Xb29370WQktbU1LQhlBQKIue97OJBco1NquR3-D_8jZ25l7SJ4rfCfcixw96EmZ3Z2Zl9BmAz9JQ2mYjtRGaxLVPl0mVlbicmxHhIJCkvD9wO-173WH4-USdr8Ke5C0NllY1NLA11dprSGTkG6dyjnJd0tyc_bOoaRdnVpoVGpRY9Pf-FIdv0w_5HlO9r193rDHe7dt1VwE6ldGZ2ooUJhDShFEniO9oPE-46aaYMulptYuULz_jIv_JSh6dKuCbLPCEVF5mRTiJw3huwLgWGMi1Y3-n0B0eLvIX0y-aVXCjKrwayAUQVwbsxoWNyf4uay19xgauO4IonXK3SXEnVlh5w7y7cqbeurF3p2j1Y08V9uFk1s5w_gN89PYvHuGm1McxHhcnYGcHCkuBZXrDxp9H5kWLxzzgfVdjgc5ZPWVyrB5LTkTCLC3xmeV2giz9xlrKKV7-nsS-c735t7wy8IMDXjA06Q5aPy05LrETKpU8tqnuLh3B8LcJ5BK3itNBPgBnNg9gYAjTUkjaqiTZBprSvKXeslQVvGylEaY2HTm05RlGZlxdBNJ5EJLFIBRa8WtBOKhSQf1K9IWFGZBpwpjSubzggPwSyFbUVGVBi1oKNJUpc0unycKMOUW1SptHlArDgcaUZC15wjxhSAtkCf0lnFgQEIr48UuTfSzBx5QnPk6EFm412XX7y77_49P-cvYRb3eHhQXSw3-89g9s4EFRVThvQmp2d6-e4gZslL-pVw-DbdS_UCxNUWeA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ta9RAEB5qRfGL-G606oIV8UNsNrubF0HkbHu2npZDWjgQiXnZxcAlPXupcr_Df-OvcyZv7Z3it0I-JNlhs2Fmdmd2Zp8B2Aw9pU0mYjuRWWzLVLl0WJnbiQnRHxJJyusNt48H3t6RfD9RkzX43Z2FobTKbk6sJ-rsOKU9cnTSuUcxL-lumTYtYrwzfDP7blMFKYq0duU0GhEZ6cVPdN_mr_d3kNfPXHe4e7i9Z7cVBuxUSqeyEy1MIKQJpUgS39F-mHDXSTNlcNnVJla-8IyP_6K81OGpEq7JMk9IxUVmpJMI7PcSXPYFvkBd8ie9s8elX5ex5EJRpDWQHTSqCLYKwsnk_ksqM39uMVxdEs6tiav5mitB23otHN6A660RywaN1N2ENV3egitNWcvFbfg10lVcoPlqo8OPopOxEwKIJRFgecmKd9PTT4rFP-J82qCEL1g-Z3ErKEhOm8MsLvGq8jZVF2-xlzqfV7-its-cb38ZvB17QYCPGRvvHrK8qGsusRozlz7V5_mWd-DoQlhzF9bL41LfB2Y0D2JjCNpQSzJZE22CTGlfUxRZKwtedFyI0hYZnQp0TKM6Qi-CqJhFxLFIBRY87WlnDR7IP6meEzMjmiSwpzRuzzrgeAhuKxoomkppsBZsLFGicqfLzZ04RO3kMo_OVMGCe41k9GNBazGkULIF_pLM9AQEJ77cUubfalhx5QnPk6EFm510nX3y71988P-RPYGrqJ7Rh_2D0UO4hu-DJt1pA9ark1P9CC25KnlcqwyDrxeto38AP71csA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ketamine-induced+reduction+in+mGluR5+availability+is+associated+with+an+antidepressant+response%3A+an+%5B11C%5DABP688+and+PET+imaging+study+in+depression&rft.jtitle=Molecular+psychiatry&rft.au=Esterlis%2C+I&rft.au=DellaGioia%2C+N&rft.au=Pietrzak%2C+R+H&rft.au=Matuskey%2C+D&rft.date=2018-04-01&rft.pub=Nature+Publishing+Group&rft.issn=1359-4184&rft.volume=23&rft.issue=4&rft.spage=824&rft_id=info:doi/10.1038%2Fmp.2017.58&rft.externalDocID=A531833451
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1359-4184&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1359-4184&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1359-4184&client=summon